Heba Youssef: Can Cefoperazone Cause Coagulopathy?
Heba Youssef, Clinical Nutrition Pharmacist at Helwan General Hospital, shared a post on LinkedIn:
”Cefoperazone can cause a coagulopathy that’s easy to miss. Its NMTT side chain interferes with vitamin K-dependent clotting factors, and in some patients this is made worse by suppression of gut flora that normally produces vitamin K. The result, hypoprothrombinemia, can happen with or without visible bleeding, which is exactly why it needs active monitoring rather than waiting for symptoms.
Patients at higher risk include those with poor nutrition, malabsorption, liver or biliary disease, kidney dysfunction, prolonged or high-dose therapy, or concurrent use of anticoagulants. For these patients, checking baseline and repeat PT/INR and platelet counts is a simple but important safety step.
Giving vitamin K to every patient on cefoperazone isn’t routinely recommended, since the evidence doesn’t support one standard approach. But vitamin K should be given once deficiency or drug-related coagulopathy is suspected or confirmed. A 2024 randomized trial found that 10 mg IV vitamin K weekly reduced coagulopathy and bleeding in high-risk ICU patients, an encouraging finding, though still from a single study rather than an established guideline.
If PT/INR rises unexpectedly during cefoperazone therapy, check for vitamin K deficiency and other causes before blaming the drug alone. And if bleeding continues with no other explanation, that’s a clear signal to stop the drug and follow your institution’s protocol.
References:
- FDA. CEFOBID® (cefoperazone) Prescribing Information. Revised March
- Miao W, Guo J, Cheng H, et al. Risk Factors for Cefoperazone/Sulbactam-Induced Coagulation Disorder. Infect Drug Resist. 2023;16:6277–6284.
- Ebid AI, Abdeen HA, Maher RM, Mohamed-Abdel-Motaleb SM. Cefoperazone-Sulbactam-Induced Coagulopathy in Critically Ill Egyptian Patients: Role of Vitamin K Prophylactic Doses. Hosp Pharm.
- Strom BL, Schinnar R, Gibson GA, Brennan PJ, Berlin JA. Risk of bleeding and hypoprothrombinaemia associated with NMTT side chain antibiotics: using cefoperazone as a test case. Pharmacoepidemiol Drug Saf. ”
Other posts featuring Heba Youssef on Hemostasis Today.
-
Aug 30, 2026, 07:49Elisa Rauseo: Could Cardiac CT Become the First-line Test to Exclude Left Atrial Appendage Thrombus in Acute Stroke?
-
Aug 30, 2026, 07:40Rasmus Borgquist: Silent Atherosclerosis is Far More Common Than Thought
-
Aug 30, 2026, 07:30Hamid Ashraf: The RANKL/OPG Index as a Bone Health Biomarker in Children with Haemophilia
-
Aug 30, 2026, 07:22Milad Rezvani: Aggressive B-Cell Lymphoma Presenting as Bilateral Upper-Extremity SVT
-
Aug 30, 2026, 07:12Mehrdad Zarghami: Evaluating aPL Prevalence and Recurrence Risk in Ischemic Stroke
-
Aug 30, 2026, 07:03Fabian Kurth: Celebrating Teamwork and Cardiovascular Heritage at ESC Congress 2026
-
Aug 30, 2026, 06:56Rachel Keane: Summer Clinical Research at Sinai Hospital of Baltimore
-
Aug 29, 2026, 17:05What If Factor XI inhibition Could Reshape the Future of Anticoagulation – ISTH
-
Aug 29, 2026, 16:44Nipocalimab for Warm Autoimmune Hemolytic Anemia: What the FDA Approval Means